SHARE NOW
Integra Therapeutics presented positive data from ex vivo and in vivo preclinical studies demonstrating the potential of its FiCAT gene writing platform for developing advanced therapies in pediatric hepatology at Advanced Therapies Europe.
Biotechnology company
Integra Therapeutics
presented positive data from ex vivo and in vivo preclinical
studies. Founded in 2020 as a spin-off of Pompeu Fabra University by Dr Marc
Güell and Dr Avencia Sánchez-Mejías, Integra Therapeutics has built a
solid technology platform that can write large and small genes, combining the
precision of the CRISPR-Cas9 technique. The company’s lead technology FiCAT is designed to be the next-generation of
gene writing combining proteins modified with CRISPR-Cas9 and PiggyBac
transposase cut-and-transfer module. Dr Avencia Sánchez-Mejías as part of a
panel of innovative technologies as a driving force for successful
commercialization of cell and gene therapies on the European market, analyzed
the data titled ‘FiCAT Innovative Gene Writing Platform for Advanced Therapies’.
“The ex vivo and in vivo preclinical data validates our FiCAT
gene-writing platform for developing cell and gene therapies for patients with
genetic minority and oncological diseases and is driving us to intensify our
efforts to move into the preclinical regulatory phase in the coming months,”
elaborated Sánchez-Mejías.
How are you enjoying this news article? Let us know your thoughts, here
FiCAT has been tested for ex vivo cell engineering and
in vivo therapy. Integra Therapeutics continues to expand FiCAT with
tools such as more effective alternative transposons and programmable nucleases
due to it high-performance system to detect improved genome editors and protein
design using artificial intelligence to potentially achieve safer and more
flexible, efficient, and broadly applicable gene writing. The company is
supported by international investors such as AdBio Partner, Columbus Venture
Partners, Invivo Capital and Takeda Ventures. It has also obtained the My Green
Lab sustainability certification in 2023. Source:
Integra Therapeutics Press Release</a >
While we have you…
We are continuously working to better optimize our content for you, our
audience. Let us know how we’re doing by ticking the box below, or send us your
feedback directly to
team@phacilitate.com.
